Our perspectives
in one place
Topic
Selected filters
Clear
News
See allInnovative pharmaceutical industry leaders reinforce ethics and business integrity in APEC economies and health sectors
IFPMA, with support and representation from industry leaders, joins stakeholders this week at the 11th Business Ethics for APEC SMEs Forum. This Forum – and the initiative on which it is based – supports the advancement of ethical business practices in the Asia-Pacific economies, with a focus on the health sector and wider health ecosystem....
Read moreOnly an urgent shift towards prevention-based healthcare can secure economic stability for EU health systems, experts say
As Governments of EU Member States present their medium-term fiscal structural plans on 20 September, a new report developed by The European House – Ambrosetti, supported by IFPMA and Vaccines Europe, notes that embedding preventative healthcare – in particular immunisation – into EU Member States’ fiscal policies is paramount to ensure the economic sustainability of...
Read moreEleventh meeting of the Intergovernmental Negotiating Body (INB)
On 9 September 2024, IFPMA delivered a statement at the eleventh meeting of the Intergovernmental Negotiating Body (INB) in Geneva, Switzerland. Thank you for this opportunity to continue being engaged in the INB process. The biopharmaceutical industry is committed to achieving a Pandemic Agreement that works. We believe it is possible to reach an agreement...
Read moreAMATA statement on the Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035
On 29 August at the 74th WHO Africa Regional Committee Meeting in Brazzaville, Republic of Congo, the African Medicines Agency Treaty Alliance delivered a statement on Agenda item 10: Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035.
Read moreIFPMA statement on the Framework for strengthening local production of medicines, vaccines, and other health techonologies in the WHO African Region 2025-2035
On 28 August at the 74th WHO Africa Regional Committee Meeting in Brazzaville, Republic of Congo, IFPMA submitted a statement on Agenda item 10: Framework for strengthening local production of medicines, vaccines, and other health technologies in the WHO African Region 2025-2035.
Read moreSecond meeting of the Ad Hoc Open-ended Working Group on Benefit-sharing from the Use of Digital Sequence Information (DSI)
On 12 August 2024, IFPMA delivered a statement at the second meeting of the Ad Hoc Open-ended Working Group on Benefit-sharing for the use of Digital Sequence Information (DSI) in Montreal, Canada.
Read morePublications
See allThe value of prevention for economic growth and the sustainability of healthcare, social care and welfare systems (The European House – Ambrosetti)
Read more
Sustainable access to effective antibiotics
In a new position paper, IFPMA explores some of the challenges in ensuring access to safe and quality-assured antibiotics and propose a set of policy changes for consideration.
Read more
The Value of Reference Agency Assessment Reports in Enabling Regulatory Reliance
Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...
Read more
Expert insights
See all
How empowering healthcare professional voices can build public trust and vaccine uptake
Read more
Adult immunization: Powerful new evidence for a prevention-first mindset
Read more
Now is the time for sustainable financing for NCDs and mental health
Read moreResources
See allOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
Action on NCDs: How the innovative pharmaceutical industry helps bridge the care gap
Read more